Filing Details
- Accession Number:
- 0001179110-14-018056
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2014-12-12 16:37:14
- Reporting Period:
- 2014-05-19
- Filing Date:
- 2014-12-12
- Accepted Time:
- 2014-12-12 16:37:14
- Original Submission Date:
- 2014-05-21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1280600 | Acceleron Pharma Inc | XLRN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1325710 | L Matthew Sherman | 128 Sidney Street Cambridge MA 02139 | Svp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-05-19 | 1,900 | $31.47 | 14,022 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-05-19 | 100 | $32.23 | 13,922 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $31.69, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The amount of securities beneficially owned following the reported transaction(s) in column 5 of the Form 4 filed on May 21, 2014 was overstated by 1,936 shares due to a typographical error. This error was repeated in column 5 for securities owned directly by the reporting person in all subsequent Form 4 filings by the reporting person, which includes Form 4s filed on May 30, 2014; June 13, 2014; June 20, 2014; July 11, 2014; July 22, 2014; July 25, 2014; August 13, 2014; August 15, 2014; August 19, 2014; September 4, 2014; September 19, 2014; October 9, 2014; October 20, 2014; November 14, 2014; and November 18, 2014. In these filings, the numbers in column 5 relating to securities directly owned by the reporting person should be 1,936 shares fewer than was reflected in each filing.